Biologicals

Cholera

A parenterally administered, killed whole-cell cholera vaccine has been widely available for many years. The WHO Requirements for this vaccine were first adopted in 1959 and revised in 1968; an addendum was incorporated in 1973. However, this vaccine offers at best only limited protection of short duration and produces un-pleasant side-effects in many vacinees. In view of the limitations, the vaccine has not been considered satisfactory for general public health use, and in 1973 the twenty-sixth World Health Assembly abolished the requirement in the International Health Regulations for a certificate of vaccination against cholera.

Considerable progress has been made during the past decade in the development of a new generation of oral vaccines against cholera. These have already been licensed in some countries and are now being considered for wider public health application. Two distinct types of oral cholera vaccine have been developed; those consisting of live attenuated bacteria and those consisting of killed (inactivated) bacterial cells. In some cases, the latter are combined with the purified recombinant DNA-derived B-subunit of the cholera toxin. These positive developments have led to a need for international guidance to assure the quality and safety of this new generation of cholera vaccines. The present WHO guidelines apply only to inactivated oral cholera vaccines.

Because the WHO Requirements for the production and control of the killed whole cell parenteral cholera vaccine may not be relevant to the production and control of the new generation of cholera vaccines, and because such a vaccine is no longer recommended for general public health use (although it is still produced in some countries), as well as the potential for confusion with guidelines relating specifically to the new vaccines, the Expert Committee for Biological Standardization, decided at its fiftieth meetings to discontinue those requirements.


RELATED DOCUMENTS

UPCOMING EVENTS

WHO Drafting Group Meeting on the Revision of TRS 962, Annex 1

(Guidelines to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines) 29-30 April 2014, WHO/HQ, Geneva

Implementation Workshop on Evaluation of Biotherapeutic Products and Evaluation of Similar Biotherapeutic products with emphasis on Monoclonal Antibody Products

13-16 May 2014, Seoul, The Republic of Korea

CONTACTS

Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971